Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

被引：101

作者：

Menet, Christel J. ^{[1
]}

Fletcher, Stephen R. ^{[2
]}

Van Lommen, Guy ^{[1
]}

Geney, Raphael ^{[3
]}

Blanc, Javier ^{[1
]}

Smits, Koen ^{[1
]}

Jouannigot, Nolwenn ^{[1
]}

Deprez, Pierre ^{[3
]}

van der Aar, Ellen M. ^{[1
]}

Clement-Lacroix, Philippe ^{[3
]}

Lepescheux, Lien ^{[3
]}

Galien, Rene ^{[3
]}

Vayssiere, Beatrice ^{[3
]}

Nelles, Luc ^{[1
]}

Christophe, Thierry ^{[1
]}

Brys, Reginald ^{[1
]}

Uhring, Muriel ^{[4
]}

Ciesieski, Fabrice ^{[4
]}

Van Rompaey, Luc ^{[1
]}

机构：

[1] Galapagos NV, B-2800 Mechelen, Belgium

[2] BioFocus, Saffron Walden CB10 1XL, Essex, England

[3] Galapagos SASU, F-93230 Romainville, France

[4] NovAliX, F-67405 Illkirch Graffenstaden, France

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2014年 / 57卷 / 22期

关键词：

INFLAMMATORY DISEASES; RHEUMATOID-ARTHRITIS; CYTOKINE RECEPTORS; RESTRICTED ROLE; DISCOVERY; RESPONSES; POTENT;

D O I：

10.1021/jm501262q

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohns disease (CD).

引用

页码：9323 / 9342

页数：20

共 50 条

[1] Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Van Rompaey, Luc
Galien, Rene
van der Aar, Ellen M.
Clement-Lacroix, Philippe
Nelles, Luc
Smets, Bart
Lepescheux, Lien
Christophe, Thierry
Conrath, Katja
Vandeghinste, Nick
Vayssiere, Beatrice
De Vos, Steve
Fletcher, Stephen
Brys, Reginald
van 't Klooster, Gerben
Feyen, Jean H. M.
Menet, Christel
JOURNAL OF IMMUNOLOGY, 2013, 191 (07): : 3568 - 3577
[2] An Active Metabolite Contributes To The Pharmacodynamics and Efficacy Of GLPG0634, a Selective JAK1 Inhibitor
Namour, Florence
ARTHRITIS AND RHEUMATISM, 2013, 65 : S765 - S765
[3] BIOLOGICAL EFFECTS OF THE JAK1 SELECTIVE INHIBITOR GLPG0634 ON INFLAMMATION MARKERS IN ARTHRITIC MICE
Vayssiere, B.
de Vos, S.
Merciris, D.
Auberval, M.
Dupont, S.
Vandeghinste, N.
Lepescheux, L.
Clement-Lacroix, P.
Delerive, P.
van Rompaey, L.
Brys, R.
Galien, R.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 201 - 202
[4] Influence of Age and Renal Impairment on Pharmacokinetics of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor
Florence, Namour
Fagard, Liesbeth
Van der Aa, Annegret
Goss, Sandy
Harrison, Pille
Tasset, Chantal
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[5] GLPG0634 Shows Selective Inhibition of JAK1 and Maintained JAK-STAT Suppression in Healthy Volunteers
Vanhoutte, Frederic
Galien, Rene
Vets, Eva
Namour, Florence
Vayssierre, Beatrice
Van Rompaey, Luc
Smets, Bart
Brys, Reginald
Wigerinck, Piet
van 't Klooster, Gerben
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S862 - S863
[6] ONCE-DAILY DOSING OF GLPG0634, A SELECTIVE JAK1 INHIBITOR, IS SUPPORTED BY ITS ACTIVE METABOLITE
Namour, F.
Galien, R.
Vanhoutte, F. P.
Wigerinck, P.
van 't Klooster, G.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 244 - 245
[7] GLPG0634, A SELECTIVE JAK1 INHIBITOR, CONFIRMS ITS LOW LIABILITY FOR DRUG-DRUG INTERACTIONS
Namour, F.
Desrivot, J.
Tasset, C.
Van der Aa, A.
van't Klooster, G.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 960 - 960
[8] GLPG0634M1, A MAJOR METABOLITE OF THE JAK1-SELECTIVE INHIBITOR GLPG0634, IS ALSO JAK1-SELECTIVE AND EFFICIENT IN THE RAT CIA MODEL
Belleville-Da-Costa, C.
Merciris, D.
Vayssiere, B.
Houvenaghel, N.
Monjardet, A.
Lepescheux, L.
Dupont, S.
Christophe, T.
Borgonovi, M.
Clement-Lacroix, P.
Menet, C.
Van Rompaey, L.
Brys, R.
Galien, R.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 226 - 227
[9] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
Florence Namour
Paul Matthias Diderichsen
Eugène Cox
Béatrice Vayssière
Annegret Van der Aa
Chantal Tasset
Gerben Van‘t Klooster
Clinical Pharmacokinetics, 2015, 54 : 859 - 874
[10] GLPG0634, the first selective JAK1 inhibitor, shows strong activity in the mouse DSS-colitis model
Merciris, D.
Delachaume, C.
De Vriendt, V.
Boutet, A-L
Perret, L.
Ceccotti, M-C
De Vos, S.
Monjardet, A.
Brys, R.
Galien, R.
JOURNAL OF CROHNS & COLITIS, 2014, 8 : S92 - S92

← 1 2 3 4 5 →